Carlos Williams
Neurology · South Hill, VANPI 1669464855
Payments from drug & device makers
Across 75 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$601
- AbbVie$202
- Argenx US, Inc.$141
- UCB, Inc.$116
- Livanova USA, Inc.$77
- Eisai Inc.$63
- plus $341 from 13 others
What the payments were for
- Food & beverage$1,541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 33 | $601 |
| AbbVie(2 entities) | 11 | $202 |
| Argenx US, Inc. | 6 | $141 |
| UCB, Inc. | 1 | $116 |
| Livanova USA, Inc. | 4 | $77 |
| Eisai Inc. | 3 | $63 |
| Lundbeck LLC | 3 | $59 |
| SK Life Science, Inc. | 2 | $49 |
| Abbott | 1 | $41 |
| Amgen | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 1 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| GE HealthCare | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Briviact$116
How this compares
$1,541 in reported general payments places this provider in the 45th percentile of 474 neurology providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 11 | $174,110 |
| BetaseronInterferon Beta-1b | 14 | $127,906 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $102,754 |
| AptiomEslicarbazepine Acetate | 25 | $46,713 |
| Memantine Hcl | 306 | $13,557 |
| Oxtellar XrOxcarbazepine | 16 | $8,330 |
| LamictalLamotrigine | 12 | $8,140 |
| Duloxetine Hcl | 291 | $6,609 |
| Levetiracetam | 273 | $5,675 |
| Carbamazepine ErCarbamazepine | 33 | $5,557 |
| Oxcarbazepine | 74 | $4,070 |
| Primidone | 118 | $3,738 |
| Memantine Hcl ErMemantine Hcl | 17 | $3,548 |
| Quetiapine Fumarate | 174 | $3,432 |
| Carbamazepine | 56 | $3,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Aptiom | $27 | $46,71325 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $17 | $8,33016 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $24 | $81014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 474 neurology providers in Virginia.
Other neurology in South Hill
- Yasir Al-KhaliliSouth Hill$81K
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Ramsey FalconerAlexandria$2.4M
- Robert ShinCharlottesville$2.2M
- Simon FishmanAlexandria$1.6M
- Ingrid Loma MillerNorfolk$1.2M
- Matthew BarrettHenrico$1.1M
- James BickselMc Lean$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.